ReviewBrain sciences2023
Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review.
Review in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07790744 (A Comprehensive, Multimodal Characterization of Prodromal PD in Subjects With RBD), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Comprehensive, Multimodal Characterization of Prodromal PD in Subjects With RBD
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Short term cardiovascular symptoms improvement after deep brain stimulation in patients with Parkinson's disease: a systematic review.Journal of neurology · 2024Pooled it
- Equivocal Dopamine Transporter Imaging: Integrating Visual Assessment, Quantification, and Clinical Follow-Up.Life (Basel, Switzerland) · 2026Review
- Bidirectional Mechanisms Linking Circadian Rhythm Disruption and Parkinson's Disease: Chronobiomarkers and Therapeutic Implications.International journal of molecular sciences · 2026Review
- A cross-sectional study of autonomic dysfunction in patients with Parkinson's disease and vascular parkinsonism.Acta neurologica Belgica · 2026Article
- Heart rate monitoring using wrist photoplethysmography in Parkinson disease: feasibility and relation with autonomic dysfunction.Journal of neuroengineering and rehabilitation · 2026Article
- The role of neuro-imaging in multiple system atrophy.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Combined Striatal Dopaminergic and Cardiac Sympathetic Imaging in Parkinson's Disease.Brain sciences · 2026Review
- Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice.Movement disorders clinical practice · 2026Article
- Machine learning for automated differentiation of parkinson's disease and its mimics using ¹²³I-mIBG scintigraphy: insights from a multicentre real-world cohort (ITA-mIBG study).European journal of nuclear medicine and molecular imaging · 2026Article
- Cardiorespiratory Response to Exercise in Parkinson's Disease: Associations with Autonomic Dysfunction and Physical Activity.Movement disorders clinical practice · 2025Article
- Review
- The neuronal imaging in cardiology: 123I-Biophysical reviews · 2025Review
- Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders.European journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Clinical correlates of data-driven subtypes of deep gray matter atrophy and dopamine availability in early Parkinson's disease.NPJ Parkinson's disease · 2025Article
- The Usefulness of 131 I-MIBG Myocardial Scintigraphy in a Case of Pure Autonomic Failure - First Report in the Literature.Annals of Indian Academy of Neurology · 2025Article
- Review
- Value of multi-parameterEJNMMI research · 2025Article
- Development and validation of a novel scoring system integrating MIBG scintigraphy and SPECT imaging for differentiating Parkinson's disease.Frontiers in neurology · 2025Article
- Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac sympathetic denervation, as documented on 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, is relatively sensitive and specific for distinguishing Parkinson's disease (PD) from other neurodegenerative causes of parkinsonism. The present study aims to comprehensively review the literature regarding the use of cardiac MIBG in PD. MIBG is an analog to norepinephrine. They share the same uptake, storage, and release mechanisms. An abnormal result in the cardiac MIBG uptake in individuals with parkinsonism can be an additional criterion for diagnosing PD. However, a normal result of cardiac MIBG in individuals with suspicious parkinsonian syndrome does not exclude the diagnosis of PD. The findings of cardiac MIBG studies contributed to elucidating the pathophysiology of PD. We investigated the sensitivity and specificity of cardiac MIBG scintigraphy in PD. A total of 54 studies with 3114 individuals diagnosed with PD were included. The data were described as means with a Hoehn and Yahr stage of 2.5 and early and delayed registration H/M ratios of 1.70 and 1.51, respectively. The mean cutoff for the early and delayed phases were 1.89 and 1.86. The sensitivity for the early and delayed phases was 0.81 and 0.83, respectively. The specificity for the early and delayed phases were 0.86 and 0.80, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.